191 related articles for article (PubMed ID: 33400240)
1. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
Rohrberg KS; Lassen U
Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
[TBL] [Abstract][Full Text] [Related]
2. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
[TBL] [Abstract][Full Text] [Related]
3. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
[TBL] [Abstract][Full Text] [Related]
5. A novel EML4-NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib.
Batra U; Nathany S; Sharma M; Jain P; Mehta A; Bansal A
J Cancer Res Ther; 2023 Oct; 19(7):2045-2047. PubMed ID: 38376315
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors.
Acharya B; Saha D; Garcia Garcia N; Armstrong D; Jabali B; Hanafi M; Frett B; Ryan KR
Bioorg Med Chem; 2024 May; 106():117749. PubMed ID: 38744018
[TBL] [Abstract][Full Text] [Related]
7. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
Laetsch TW
Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
[No Abstract] [Full Text] [Related]
8. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
Farina AR; Cappabianca L; Ruggeri P; Gneo L; Pellegrini C; Fargnoli MC; Mackay AR
J Exp Clin Cancer Res; 2018 Jun; 37(1):119. PubMed ID: 29914559
[TBL] [Abstract][Full Text] [Related]
9. ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.
Schmid S; Russell ZR; Yamashita AS; West ME; Parrish AG; Walker J; Rudoy D; Yan JZ; Quist DC; Gessesse BN; Alvinez N; Cimino PJ; Kumasaka DK; Parchment RE; Holland EC; Szulzewsky F
bioRxiv; 2024 Mar; ():. PubMed ID: 38558981
[TBL] [Abstract][Full Text] [Related]
10.
Whaley RD; Tekin B; McCarthy MR; Zia HM; Pitel BA; Al-Kateb H; Cheville JC; Gupta S
Int J Surg Pathol; 2024 May; ():10668969241253197. PubMed ID: 38772598
[TBL] [Abstract][Full Text] [Related]
11. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Weis LN; Tolaney SM; Barrios CH; Barroso-Sousa R
NPJ Breast Cancer; 2021 Sep; 7(1):120. PubMed ID: 34518552
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic role of a developmentally regulated
Pattwell SS; Arora S; Nuechterlein N; Zager M; Loeb KR; Cimino PJ; Holland NC; Reche-Ley N; Bolouri H; Almiron Bonnin DA; Szulzewsky F; Phadnis VV; Ozawa T; Wagner MJ; Haffner MC; Cao J; Shendure J; Holland EC
Sci Adv; 2022 Oct; 8(40):eabo6789. PubMed ID: 36206341
[TBL] [Abstract][Full Text] [Related]
13. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
Rosen EY; Schram AM; Young RJ; Schreyer MW; Hechtman JF; Shu CA; Ku NC; Hyman DM; Drilon A
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914009
[No Abstract] [Full Text] [Related]
14. How selecting best therapy for metastatic
Ekman S
Transl Lung Cancer Res; 2020 Dec; 9(6):2535-2544. PubMed ID: 33489816
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors.
Forsythe A; Zhang W; Phillip Strauss U; Fellous M; Korei M; Keating K
Ther Adv Med Oncol; 2020; 12():1758835920975613. PubMed ID: 33425024
[TBL] [Abstract][Full Text] [Related]
16. Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With
Dunn DB
J Adv Pract Oncol; 2020; 11(4):418-423. PubMed ID: 33604102
[TBL] [Abstract][Full Text] [Related]
17. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
[TBL] [Abstract][Full Text] [Related]
18. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
Jiang T; Wang G; Liu Y; Feng L; Wang M; Liu J; Chen Y; Ouyang L
Acta Pharm Sin B; 2021 Feb; 11(2):355-372. PubMed ID: 33643817
[TBL] [Abstract][Full Text] [Related]
19. Gene Fusion Identification Using Anchor-Based Multiplex PCR and Next-Generation Sequencing.
Cheng YW; Meyer A; Jakubowski MA; Keenan SO; Brock JE; Azzato EM; Weindel M; Farkas DH; Rubin BP
J Appl Lab Med; 2021 Jul; 6(4):917-930. PubMed ID: 33537766
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
